Zita-Pio Tablet is a combination oral hypoglycemic agent containing Teneligliptin 20 mg and Pioglitazone 15 mg, indicated for the management of type 2 diabetes mellitus. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone levels, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner, which aids in improving glycemic control. Pioglitazone, a thiazolidinedione class drug, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved peripheral glucose uptake and reduced hepatic glucose production. The combination therapy offers complementary mechanisms, providing effective glycemic control in patients inadequately controlled by diet and exercise alone or monotherapy. Zita-Pio Tablet should be used as part of a comprehensive diabetes management plan that includes diet, exercise, and regular monitoring of blood glucose levels. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, active liver disease, or heart failure. Common adverse effects may include edema, weight gain, and gastrointestinal disturbances. Regular monitoring of liver function tests and cardiovascular status is recommended during therapy. Dose adjustments may be necessary based on renal and hepatic function. Zita-Pio Tablet should be prescribed and used under medical supervision.